Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Medigen Vaccine Biologics Corporation is a biotech pharmaceutical enterprise specializing in the creation and manufacturing of vaccines and biological treatments, catering to markets both within Taiwan and globally. Its robust pipeline features several key candidates: An enterovirus A71 vaccine, currently undergoing Phase III clinical trials, aimed at combating enterovirus infections. An influenza vaccine that has successfully concluded Phase III clinical trials for influenza treatment. A dengue vaccine, having finished Phase II clinical trials, designed to address dengue fever. A respiratory syncytial virus (RSV) antibody, in Phase I trials, intended for preventing RSV infections. And a COVID-19 vaccine, presently in Phase III clinical studies, developed to avert COVID-19 and severe special infectious pneumonia. Established in 2012, this Taipei, Taiwan-headquartered company operates as a subsidiary of Medigen Biotechnology Corp.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E.